The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Leont'ev S.G.
Kafedra fakul'tetskoĭ khirurgii im. S.I. Spasokukotskogo Rossiĭskogo gosudarstvennogo meditsinskogo universiteta im. N.I. Pirogova, Moskva
Mironov A.V.
NII SP im. N.V. Sklifosovskogo
Ustinov F.S.
Gorodskaia klinicheskaia bol'nitsa #1 im. N.I. Pirogova, Moskva
Complications of thrombolythic therapy of massive pulmonary embolism
Journal: Journal of Venous Disorders. 2013;7(1): 55‑61
Views: 8090
Downloaded: 109
To cite this article:
Leont'ev SG, Mironov AV, Ustinov FS. Complications of thrombolythic therapy of massive pulmonary embolism. Journal of Venous Disorders. 2013;7(1):55‑61. (In Russ.)
Thrombolytic therapy is a highly effective method for restoring the patency of the lung arterial bed in the patients presenting with massive pulmonary embolism. At the same time, the application of fibrinolytic agents is fraught with the high risk of anaphylactic reactions and hemorrhages of differing severity. The present paper is a review of the literature data concerning the results and complications of thrombolytic therapy with the use of various fibrinolytic agents for the management of massive pulmonary embolism. The most common problems pertinent to the application of modern thrombolytic medicines are discussed. The comparative analysis of the frequency of development of "major" and "minor" hemorrhages associated with the use of fibrin-specific (tissue plasminogen activators) and fibrin-nonspecific (streptokinase, urokinase) preparations is undertaken. The analysis included the assessment of the relationship between the risk of the development of hemorrhagic complications and the mechanisms of action of thrombolytic preparations. The possibilities of using fibrinolytic agents in the patients at high risk of thrombolytic complications are considered with special reference to pharmacological cost effectiveness of thrombolysis for the treatment of the patients with massive pulmonary embolism.
Authors:
Leont'ev S.G.
Kafedra fakul'tetskoĭ khirurgii im. S.I. Spasokukotskogo Rossiĭskogo gosudarstvennogo meditsinskogo universiteta im. N.I. Pirogova, Moskva
Mironov A.V.
NII SP im. N.V. Sklifosovskogo
Ustinov F.S.
Gorodskaia klinicheskaia bol'nitsa #1 im. N.I. Pirogova, Moskva
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.